Modulating T-cell-based cancer immunotherapy via particulate systems
Immunotherapy holds tremendous promise for improving cancer treatment in which an
appropriate stimulator may naturally trigger the immune system to control cancer. Up-to …
appropriate stimulator may naturally trigger the immune system to control cancer. Up-to …
'Atypical'CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors
DE Gilham, J Maher - Immunotherapy, 2017 - Taylor & Francis
Chimeric antigen receptor (CAR) T-cell therapy has recently been recommended for
approval for certain B-cell malignancies bringing the approach closer to mainstream cancer …
approval for certain B-cell malignancies bringing the approach closer to mainstream cancer …
CAR-T 细胞在肿瘤治疗中的研究进展
赵玲娣， 高全立 - 中国肿瘤临床, 2015 - cjco.cn
以嵌合型抗原受体(chimeric antigen receptor, CAR) 为基础的细胞免疫治疗是一种新的治疗
恶性肿瘤的模式, 为部分晚期实体瘤患者带来治愈的希望. 选择合适的目标靶分子 …
恶性肿瘤的模式, 为部分晚期实体瘤患者带来治愈的希望. 选择合适的目标靶分子 …
Current headway in cancer immunotherapy emphasizing the practice of genetically engineered T cells to target selected tumor antigens
SK Ray, S Mukherjee - Critical Reviews™ in Immunology, 2021 - dl.begellhouse.com
Genetically engineered T-cell therapies have the adeptness to modernize and revolutionize
the treatment of cancer. Cancer immunotherapy, by depending on this fundamental …
the treatment of cancer. Cancer immunotherapy, by depending on this fundamental …
T-cell therapies for T-cell lymphoma
T-cell lymphomas represent a subpopulation of non-Hodgkin lymphomas with poor
outcomes when treated with conventional chemotherapy. A variety of novel agents have …
outcomes when treated with conventional chemotherapy. A variety of novel agents have …
[HTML][HTML] Genetically engineered CAR T-immune cells for cancer therapy: recent clinical developments, challenges, and future directions
SM El-Daly, J Hussein - Journal of Applied Biomedicine, 2019 - jab.zsf.jcu.cz
Cancer immunotherapy offers tremendous clinical outcomes in cancer management with the
potential to induce sustained remission in patients with refractory disease. One of these …
potential to induce sustained remission in patients with refractory disease. One of these …
Exploiting cytokines in adoptive T-cell therapy of cancer
E Petrozziello, T Sturmheit, A Mondino - Immunotherapy, 2015 - Taylor & Francis
Adoptive immunotherapy with tumor-reactive autologous T cells, either expanded from tumor
specimens or genetically engineered to express tumor-reactive T-cell receptors and …
specimens or genetically engineered to express tumor-reactive T-cell receptors and …
[HTML][HTML] Assessment of current gene therapy practices in hepatocellular carcinoma
B Mckiver, MI Damaj, D Sarkar - Gastrointestinal Disorders, 2020 - mdpi.com
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and the
fifth most common cancer worldwide. HCC is recognized as the fourth most common cause …
fifth most common cancer worldwide. HCC is recognized as the fourth most common cause …
[HTML][HTML] Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China
C Luo, J Wei, W Han - Science China Life Sciences, 2016 - Springer
T cell mediated adoptive immune response has been characterized as the key to anti-tumor
immunity. Scientists around the world including in China, have been trying to harness the …
immunity. Scientists around the world including in China, have been trying to harness the …
[HTML][HTML] Chronic inflammation: is it the driver or is it paving the road for malignant transformation?
K Afrasiabi, YH Zhou, A Fleischman - Genes & cancer, 2015 - ncbi.nlm.nih.gov
Chronic inflammation in well-defined mouse models such as Giα2 knock out mouse has
been shown to trigger formation and expansion of hypoxic niches and also leads to up …
been shown to trigger formation and expansion of hypoxic niches and also leads to up …